Abstract | BACKGROUND/AIMS: METHODS: We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological examination, who showed a significant decrease in the size of his liver lesions after bevacizumab treatment. Histology of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma endothelial cells. To date, surgical resection provides the only consistently effective method for treatment of hepatic hemangioma. CONCLUSIONS: This is the first documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bevacizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.
|
Authors | Dipti Mahajan, Charles Miller, Kenzo Hirose, Arthur McCullough, Lisa Yerian |
Journal | Journal of hepatology
(J Hepatol)
Vol. 49
Issue 5
Pg. 867-70
(Nov 2008)
ISSN: 0168-8278 [Print] Netherlands |
PMID | 18814928
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Adenocarcinoma
(pathology, therapy)
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Colorectal Neoplasms
(pathology, therapy)
- Hemangioma, Cavernous
(pathology, therapy)
- Humans
- Liver Neoplasms
(pathology, therapy)
- Male
- Middle Aged
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
|